Chicago-based Green Thumb Industries is the latest cannabis company to abandon hope of a U.S. IPO in favor of a reverse takeover in Canada and access to growth capital.
Cigna CEO David Cordani is game on in trying to shape the future of healthcare. He talks with TheStreet on where he thinks things are headed.
The drugmaker's presentations at ASCO's annual meeting included data on Keynote-407, which Credit Suisse analyst Vamil Divan described as a 'clear positive.'
The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.
There has been an outbreak of the liver disease in West Virginia and Kentucky.
The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.
Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
Welcome to the future of healthcare. That future includes the use of AI to improve patient outcomes.
These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.
Everyone from Amazon to Berkshire Hathaway to Cigna is trying to shape the future of healthcare. Here are eight key trends to watch.
The EpiPen maker saw a 19% drop in North America net sales due in part to lower sales of branded products.
The appointment of Mike Weinstein as senior vice president of strategy has sparked the question of what the med tech firm should do to unlock shareholder value.
The Dublin-based drugmaker will provide communications on the strategic review in 'weeks, not months,' Allergan CFO Matthew Walsh said at the Deutsche Bank healthcare conference.
Jim Cramer and our other experts look at Estee Lauder, 'special dividends' and oncology stocks.